Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: February 1, 2023

Details for Patent: 8,617,595

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,617,595 protect, and when does it expire?

Patent 8,617,595 protects TEKTURNA and is included in one NDA.

Protection for TEKTURNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-one patent family members in twenty-three countries.

Summary for Patent: 8,617,595
Title:Galenic formulations of organic compounds
Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.
Inventor(s): Rigassi-Dietrich; Petra G (Therwil, CH), Schmid; Martin (Wettingen, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:10/590,398
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,617,595
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Use; Formulation; Process;

Drugs Protected by US Patent 8,617,595

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-001 Mar 5, 2007 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-002 Mar 5, 2007 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,617,595

PCT Information
PCT FiledMarch 16, 2005PCT Application Number:PCT/EP2005/002798
PCT Publication Date:September 29, 2005PCT Publication Number: WO2005/089729

International Family Members for US Patent 8,617,595

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 048431 See Plans and Pricing
Australia 2005224010 See Plans and Pricing
Australia 2009202069 See Plans and Pricing
Brazil PI0508833 See Plans and Pricing
Canada 2554633 See Plans and Pricing
China 103462913 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.